Renaissance Technologies LLC Buys 162,100 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

Renaissance Technologies LLC grew its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,118,000 shares of the company's stock after purchasing an additional 162,100 shares during the period. Renaissance Technologies LLC owned approximately 1.52% of Protalix BioTherapeutics worth $2,102,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in PLX. Virtu Financial LLC bought a new stake in Protalix BioTherapeutics during the 3rd quarter worth about $44,000. Sanctuary Advisors LLC bought a new position in Protalix BioTherapeutics during the 3rd quarter worth about $38,000. Prudential Financial Inc. acquired a new position in Protalix BioTherapeutics during the 4th quarter worth approximately $68,000. PFG Investments LLC acquired a new stake in Protalix BioTherapeutics in the 4th quarter valued at $39,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Protalix BioTherapeutics during the 4th quarter worth approximately $35,000. 16.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PLX has been the topic of a number of recent research reports. StockNews.com lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. HC Wainwright increased their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Trading Up 0.2 %

Shares of PLX traded up $0.01 during trading hours on Thursday, reaching $3.08. 131,445 shares of the company's stock traded hands, compared to its average volume of 469,533. Protalix BioTherapeutics, Inc. has a 12 month low of $0.82 and a 12 month high of $3.10. The firm's 50 day simple moving average is $2.48 and its 200-day simple moving average is $2.06. The stock has a market cap of $239.95 million, a PE ratio of -23.65 and a beta of 0.46.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.